|
FOXO1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.4432899320127E-15 |
| Normal-vs-Stage2 |
1.75000000002257E-06 |
| Normal-vs-Stage3 |
2.22044604925031E-16 |
| Normal-vs-Stage4 |
2.14717132962505E-12 |
| Stage1-vs-Stage2 |
2.254200E-01 |
| Stage1-vs-Stage3 |
1.301980E-02 |
| Stage1-vs-Stage4 |
2.937600E-02 |
| Stage2-vs-Stage3 |
5.600700E-03 |
| Stage2-vs-Stage4 |
1.036280E-02 |
| Stage3-vs-Stage4 |
7.594000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
8.371900E-04 |
| Normal-vs-Asian |
6.48370246381091E-14 |
| Caucasian-vs-AfricanAmerican |
1.187360E-01 |
| Caucasian-vs-Asian |
1.886810E-01 |
| AfricanAmerican-vs-Asian |
4.699500E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.99618099827603E-13 |
| Normal-vs-Female |
1.62470037423645E-12 |
| Male-vs-Female |
9.305900E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.63868918434673E-12 |
| Normal-vs-Age(41-60Yrs) |
8.07132138902489E-14 |
| Normal-vs-Age(61-80Yrs) |
7.78266340262235E-14 |
| Normal-vs-Age(81-100Yrs) |
1.039010E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.285000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.888400E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.151400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.154430E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.880400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.730200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.60710000862707E-10 |
| Classical-VS-Follicular |
1.369180E-04 |
| Classical-VS-Other |
4.923800E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
1.80644388336759E-12 |
| Tall-VS-Other |
3.061700E-02 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
8.391500E-02 |
| Follicular-VS-Normal |
3.58799999999881E-06 |
| Other-VS-Normal |
2.822900E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.32209823486573E-13 |
| Normal-vs-N1 |
5.58886270596304E-13 |
| N0-vs-N1 |
2.230200E-02 |
|
|
